112 related articles for article (PubMed ID: 16822063)
1. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity.
Hsiao JK; Law B; Weissleder R; Tung CH
J Biomed Opt; 2006; 11(3):34013. PubMed ID: 16822063
[TBL] [Abstract][Full Text] [Related]
2. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.
Madsen MA; Deryugina EI; Niessen S; Cravatt BF; Quigley JP
J Biol Chem; 2006 Jun; 281(23):15997-6005. PubMed ID: 16611636
[TBL] [Abstract][Full Text] [Related]
3. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
4. Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
Rezaee M; Chen L; Kramer RH
Int J Cancer; 1987 Dec; 40(6):823-9. PubMed ID: 3692627
[TBL] [Abstract][Full Text] [Related]
5. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin.
Wilcox SA; Reho T; Higgins PJ; Tominna-Sebald E; McKeown-Longo PJ
Biochem Cell Biol; 1996; 74(6):899-910. PubMed ID: 9164658
[TBL] [Abstract][Full Text] [Related]
6. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
[TBL] [Abstract][Full Text] [Related]
7. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
Tsuchiya H; Katsuo S; Matsuda E; Sunayama C; Tomita K; Ueda Y; Binder BR
Gen Diagn Pathol; 1995 May; 141(1):41-8. PubMed ID: 8542506
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Reilly D; Andreasen PA; Duffy MJ
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
[TBL] [Abstract][Full Text] [Related]
9. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
Law B; Curino A; Bugge TH; Weissleder R; Tung CH
Chem Biol; 2004 Jan; 11(1):99-106. PubMed ID: 15112999
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of [
Vangestel C; Thomae D; Van Soom J; Ides J; Wyffels L; Pauwels P; Stroobants S; Van der Veken P; Magdolen V; Joossens J; Augustyns K; Staelens S
Contrast Media Mol Imaging; 2016 Nov; 11(6):448-458. PubMed ID: 27558262
[TBL] [Abstract][Full Text] [Related]
12. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
[TBL] [Abstract][Full Text] [Related]
13. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
14. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
16. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Grøndahl-Hansen J; Ralfkiaer E; Kirkeby LT; Kristensen P; Lund LR; Danø K
Am J Pathol; 1991 Jan; 138(1):111-7. PubMed ID: 1702928
[TBL] [Abstract][Full Text] [Related]
17. Serine proteinase activation in esophageal cancer.
Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
19. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
Okusa Y; Ichikura T; Mochizuki H; Shinomiya N
Int J Oncol; 2000 Nov; 17(5):1001-5. PubMed ID: 11029504
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HJ
Cancer; 1988 Aug; 62(3):531-3. PubMed ID: 3134120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
